Magnolol as a promising multitarget agent for Alzheimer's disease: Evidence from a systematic evidence synthesis, network pharmacology, and molecular dynamics simulations.
PhytomedicineJul 14, 2026 (epub)
Yiying Qin, Xiaoyu Dong, Chong Zhang et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review evaluated the therapeutic effects of magnolol (MN) in preclinical Alzheimer's disease models, integrating network pharmacology and molecular dynamics simulations. The study found that MN improved cognitive deficits and neuropathology through various mechanisms, identifying 60 common targets and highlighting ERBB2 as a novel stable target. The binding energies for key targets were below -4.0 kcal/mol.
Key findings
- MN improved cognitive deficits and neuropathology through antioxidant and anti-inflammatory activities.
- Network pharmacology identified 60 common targets, with five hub genes including AKT1 and ERBB2.
- Molecular docking showed binding energies below -4.0 kcal/mol for all five targets.
- The ERBB2-MN complex exhibited the lowest RMSD of 1.2 Å in MD simulations.
Why it matters
Understanding the multi-target effects of magnolol on Alzheimer's disease could inform future drug development strategies. The identification of stable targets like ERBB2 may lead to more effective therapeutic interventions.